The programmed death-1 (PD-1) costimulatory pathway has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. We investigated the role of this pathway in establishing an immune privilege status of corneal allografts in mice. B7-H1, but not B7-DC or PD-1, was expressed constitutively in the eye, i.e., cornea, iris-ciliary body, and retina. After corneal allografting, PD-1(+)CD4(+) T cells infiltrated and adhered with B7-H1(+) corneal endothelium. Blockade of PD-1 or B7-H1, but not B7-DC, led to accelerated corneal allograft rejection. In B7-H1-expressing corneal allografts, apoptosis of the infiltrating PD-1(+)CD4(+) or CD8(+) T cells was observed, after which there was allograft acceptance. In contrast, B7-H1 blockade suppressed apoptosis of infiltrating PD-1(+) T cells, which led to allograft rejection. In vitro, destruction of corneal endothelial cells by alloreactive T cells was enhanced when the cornea was pretreated with anti-B7-H1 Ab. This is the first demonstration that the constitutive expression of B7-H1 plays a critical role in corneal allograft survival. B7-H1 expressed on corneal endothelial cells maintains long-term acceptance of the corneal allografts by inducing apoptosis of effector T cells within the cornea.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4049/jimmunol.177.9.5928 | DOI Listing |
Cell Rep Med
January 2025
Department of Ophthalmology, Keio University School of Medicine, Shinjuku-ku 160-8582, Tokyo, Japan; Department of Clinical Regenerative Medicine, Fujita Medical Innovation Center, Fujita Health University, Ota-ku, Tokyo 144-0041, Japan. Electronic address:
A first-in-human investigator-initiated clinical study of a corneal endothelial cell substitute (CLS001) derived from a clinical-grade induced pluripotent stem cell (iPSC) line shows improvement of visual acuity and corneal stromal edema, with no adverse events for up to 1 year after surgery for the treatment of bullous keratopathy. While preclinical tests, including multiple whole-genome analysis and tumorigenicity tests adhering to the Food and Drug Administration (FDA) draft guidelines, are negative, an additional whole-genome analysis conducted on transplanted CLS001 cells reveals a de novo in-frame deletion of exon22 in the EP300 gene. No adverse events related to the mutation are observed.
View Article and Find Full Text PDFTransplantation
January 2025
UCL Institute of Ophthalmology, London, United Kingdom.
PLOS Glob Public Health
December 2024
Laboratory Biology, Engineering and Imaging for Ophthalmology, Health Innovation Campus, Faculty of Medicine, University Jean Monnet, Saint-Etienne, France.
Corneal graft (keratoplasty) is the most common allograft in the world, but the imbalance between the number of donors and the number of patients waiting for transplants is abysmal on a global scale and varies enormously from one country to another. The risk of transmission of systemic diseases from donor to recipient is demonstrably low. In over 50 years and an estimated 2.
View Article and Find Full Text PDFIndian J Ophthalmol
December 2024
Department of Ophthalmology, Swiss Vision Eye Group, Istanbul, Turkey.
Objectives: To demonstrate corneal remodeling after corneal allograft intrastromal ring segment (CAIRS) with an anterior-segment optical coherence tomography (AS-OCT).
Design: A prospective observational single-center study.
Methods: This observational study included keratoconus patients who underwent CAIRS implantation into a stromal tunnel.
Clin Exp Optom
December 2024
Centre for Vision and Eye Research, Queensland University of Technology, Brisbane, Queensland, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!